Bio-Techne Corporation logo
TECHBio-Techne Corporation

Debt to Assets Ratio: 11.38%

popular:market cap|pe ratio|revenue|price history|total return

Is the debt to assets ratio high or low?

The debt to assets ratio of 11.38% is 28% below its 5-year average of 15.85%, near the low end of its 5-year range (11.38%–20.35%).

As of Saturday, June 27, 2026. 23.39% below its 12-month average of 14.86%.

Debt/Equity|Total Debt|Total Assets|Interest Coverage|All Metrics
Debt to Assets

TECH Debt to Assets Ratio

11.38%

Reported quarterly debt to assets ratio; no daily interpolation.

-38.75% 5Y
TECH Debt to Assets Ratio

TECH Average Debt to Assets Ratio Chart

TECH Debt to Assets Ratio

TECH Current vs Average Debt to Assets Ratio Chart

TECH Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

11.38%

DEBT TO ASSETS RATIO AVG TTM

14.86%

DEBT TO ASSETS RATIO AVG 3Y

16.39%

DEBT TO ASSETS RATIO AVG 5Y

15.85%

DEBT TO ASSETS RATIO AVG 10Y

19.29%

DEBT TO ASSETS RATIO AVG 15Y

14.44%

DEBT TO ASSETS RATIO AVG 20Y

11.01%

CURRENT VS TTM AVG

-23.39%

CURRENT VS 3Y AVG

-30.57%

CURRENT VS 5Y AVG

-28.18%

CURRENT VS 10Y AVG

-40.99%

CURRENT VS 15Y AVG

-21.15%

CURRENT VS 20Y AVG

+3.41%

TECH Competitors' Debt to Assets Ratio

NAMEMARKET CAPDEBT TO ASSETS RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B11.38%14.86%16.39%15.85%
Insulet Corp. (PODD)vs ›$10.96B0.33%N/AN/AN/A
Baxter International Inc. (BAX)vs ›$11.38B0.50%N/AN/AN/A
Molina Healthcare, Inc. (MOH)vs ›$11.79B0.25%N/AN/AN/A
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.42%N/AN/AN/A
Charles River Laboratories International, Inc. (CRL)vs ›$10.20B0.43%N/AN/AN/A
Tempus AI, Inc. (TEM)vs ›$9.80B0.58%N/AN/AN/A
Henry Schein, Inc. (HSIC)vs ›$9.68B0.33%N/AN/AN/A
Revvity, Inc. (RVTY)vs ›$12.61B0.29%N/AN/AN/A
Align Technology, Inc. (ALGN)vs ›$12.78B0.02%N/AN/AN/A

Leverage Ratios Comparison

Debt/Assets

11.4%

Debt/Equity

0.23

Current Ratio

3.46

Interest Coverage

12.0x

Formula: Debt/Assets = Total Debt / Total Assets × 100

Debt/Assets vs Debt/Equity:

  • Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
  • Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
  • Both measure leverage but from different perspectives

Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.

Debt to Assets Ratio Formula & Definition

Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Bio-Techne Corporation (TECH)?
The debt to assets ratio for TECH stock is 11.38%.
Is Bio-Techne Corporation's debt to assets ratio high or low?
The debt to assets ratio of 11.38% is 28% below its 5-year average of 15.85%, near the low end of its 5-year range (11.38%–20.35%).
What is the TTM average debt to assets ratio for Bio-Techne Corporation (TECH)?
The TTM average debt to assets ratio for TECH stock is 14.86%.
What is the 3Y average debt to assets ratio for Bio-Techne Corporation (TECH)?
The 3Y average debt to assets ratio for TECH stock is 16.39%.
What is the 5Y average debt to assets ratio for Bio-Techne Corporation (TECH)?
The 5Y average debt to assets ratio for TECH stock is 15.85%.
What is the 10Y average debt to assets ratio for Bio-Techne Corporation (TECH)?
The 10Y average debt to assets ratio for TECH stock is 19.29%.
What is the 15Y average debt to assets ratio for Bio-Techne Corporation (TECH)?
The 15Y average debt to assets ratio for TECH stock is 14.44%.
What is the 20Y average debt to assets ratio for Bio-Techne Corporation (TECH)?
The 20Y average debt to assets ratio for TECH stock is 11.01%.

TECH Debt to Assets Ratio History

DATEDEBT TO ASSETS RATIO
2026-03-3111.38%
2025-12-3113.91%
2025-09-3015.62%
2025-06-3017.36%
2025-03-3116.02%
2024-12-3114.80%
2024-09-3014.58%
2024-06-3015.52%
2024-03-3118.18%
2023-12-3120.35%
2023-09-3019.94%
2023-06-3017.24%
2023-03-3118.23%
2022-12-3112.23%
2022-09-3014.53%
2022-06-3014.20%
2022-03-3114.23%
2021-12-3115.26%
2021-09-3016.62%
2021-06-3018.58%
2021-03-3114.04%
2020-12-3114.76%
2020-09-3019.44%
2020-06-3021.38%
2020-03-3124.96%
2019-12-3123.22%
2019-09-3029.52%
2019-06-3026.81%
2019-03-3127.89%
2018-12-3129.56%
2018-09-3029.99%
2018-06-3021.28%
2018-03-3124.26%
2017-12-3123.31%
2017-09-3022.10%
2017-06-3022.48%
2017-03-3123.36%
2016-12-3122.85%
2016-09-3025.02%
2016-06-3011.84%
2016-03-3114.10%
2015-12-3114.70%
2015-09-3014.91%
2015-06-3010.91%
2015-03-3117.21%
2014-12-3117.16%
2014-09-3012.27%
2014-06-301.50%
2014-03-310.00%
2013-12-310.00%
2013-09-300.00%
2013-06-300.00%
2013-03-310.98%
2012-12-310.00%
2012-09-300.00%
2012-06-300.00%
2012-03-310.00%
2011-12-310.00%
2011-09-300.00%
2011-06-300.00%
2011-03-310.00%
2010-12-310.00%
2010-09-300.00%
2010-06-300.00%
2010-03-310.00%
2009-12-310.00%
2009-09-300.00%
2009-06-300.00%
2009-03-310.00%
2008-12-310.00%
2008-09-300.00%
2008-06-300.00%
2008-03-310.00%
2007-12-310.00%
2007-09-300.00%
2007-06-300.00%
2007-03-310.00%
2006-12-310.00%
2006-09-303.37%
2006-06-303.62%
2006-03-314.01%
2005-12-314.52%
2005-09-304.50%
2005-06-304.95%
2005-03-315.37%
2004-12-314.24%
2004-09-304.54%
2004-06-304.87%
2004-03-315.17%
2003-12-315.61%
2003-09-306.05%
2003-06-306.49%
2003-03-316.89%
2002-12-316.94%
2002-09-307.15%
2002-06-307.58%

Related Metrics

Debt/EquityTotal DebtTotal AssetsInterest CoverageAll Metrics

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
www.bio-techne.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman
View full financials